New hope for myeloma patients with kidney issues: denosumab shows promise

NCT ID NCT02833610

Completed Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and monitored side effects like low calcium and bone events over 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University Hospital

Atlanta, Georgia, 30322, United States
Mass General/North Shore Cancer Center

Danvers, Massachusetts, 01923, United States
Massachusetts general Hospital

Boston, Massachusetts, 02114, United States
Newton Wellesley Hospital

Newton, Massachusetts, 02462, United States
University Hospitals of Cleveland

Cleveland, Ohio, 44106, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.